European venture capital (VC) giant, Sofinnova Partners, has closed a €725m ($815m) fund to support a range of life sciences companies through clinical development, commercialisation and global expansion.

The Crossover II fund, which exceeded its original target, will primarily be allocated towards financing around 15 clinical-stage biopharma and medtech companies progressing towards the commercial market. While most of this capital will go to European companies, Sofinnova also plans to dedicate some of the funds to best-in-class companies across the US and other regions.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Thus far, Sofinnova Partners has already allocated a portion of the fund to blood coagulation disorder specialist Hemab Therapeutics, as well as oncology-focused biotech CellCentric and chronic rhinitis-tackling medical device company Neuromark.

According to Antoine Papiernik, chair and managing partner of Sofinnova Partners, the scale of Crossover II “reflects both the maturity of the European life sciences ecosystem and the rising demand for capital that can help companies to reach global markets”.

“Europe is producing a growing number of world-class life sciences companies, and we believe they should have access to investors that can support them through the critical stages of growth and commercialisation,” Papiernik commented.

Crossover II follows a successful first raise by Sofinnova Partners, which supported companies that have since surpassed significant value-creating milestones. This includes now Nasdaq-listed Abivax, as well as Amolyt Pharma and Calliditas Therapeutics, which went on to be acquired by AstraZeneca and Asahi Kasei, respectively.

Sofinnova Partners launched the raise as some European companies in the space are struggling to obtain capital, with competition across the biopharma and medtech sectors ramping up at a rapid pace on the global stage. At the recent 2026 BIO-Europe conference held in Cologne, Germany, attendees pointed to the notable challenges around securing early-stage funding in Europe – especially in Series A.

In a previous conversation with Pharmaceutical Technology, Cedric Moreau, partner at Sofinnova Partners, noted that pension funds and big institutional investors need to allocate more funds to the biotech sector for companies in the space to flourish, and for Europe to stay competitive amid building rivalry between itself and both the US and China.

Kinam Hong, partner at Sofinnova Partners, added:  “We continue to see exceptional opportunities emerging across European life sciences. Many companies now have scientific strength, clinical validation, and leadership teams needed to compete on a global stage.”

“With Sofinnova Crossover II, we are well positioned to support that next generation of leaders while maintaining the disciplined investment approach that defined our first fund.”